ReviewJournal of clinical medicine2024
Current Approaches for Monitoring of Patients with Inflammatory Bowel Diseases: A Narrative Review.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Self-Efficacy as a Mediator Between Medication Adherence and Self-Care in Inflammatory Bowel Disease: A Multicenter Cross-Sectional Study.Journal of clinical nursing · 2026Article
- Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Evaluating the correlation of intestinal ultrasound and fecal calprotectin with endoscopic severity scores in assessing disease activity in ulcerative colitis patients.Journal of ultrasound · 2026Article
- SLC6A14 as a Key Diagnostic Biomarker for Ulcerative Colitis: An Integrative Bioinformatics and Machine Learning Approach.Biochemical genetics · 2026Article
- Correlation between intestinal ultrasound and fecal calprotectin with endoscopic severity scores for determining the activity in patients with Crohn's disease.Abdominal radiology (New York) · 2026Observational
- Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics.Frontiers in immunology · 2026Review
- Leveraging patient-reported outcomes and serum markers to predict active ulcerative colitis: a multicenter cohort.Frontiers in medicine · 2026Article
- Role of endoscopic ultrasound as a predictor of histological healing in ulcerative colitis.Annals of medicine · 2025Article
- Machine learning classification of inflammatory bowel disease activity using white blood cell subsets.BMJ open gastroenterology · 2025Article
- Beyond Fixed Thresholds: Cluster-Derived MRI Boundaries Improve Assessment of Crohn's Disease Activity.Journal of clinical medicine · 2025Article
- The Role of Imaging in Inflammatory Bowel Diseases: From Diagnosis to Individualized Therapy.Diagnostics (Basel, Switzerland) · 2025Review
- The ability of C-reactive protein-albumin ratio to predict disease activity in ulcerative colitis.Biomarkers in medicine · 2025Article
- The role of vitamin D deficiency and modifiable risk factors in patients with Crohn's disease.Frontiers in immunology · 2025Article
- Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions.Healthcare (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with inflammatory bowel diseases (IBD) require proactive monitoring both during the active phase to evaluate therapeutic response and during the remission phase to evaluate relapse or colorectal cancer surveillance. However, monitoring may vary between patients with ulcerative colitis (UC) and Crohn's disease (CD), with distinct tools and intervals.
methodsThis narrative review aims to focus on modern approaches to IBD monitoring, considering international guidelines and expert consensus.
resultsThe most recent European diagnostic guidelines advocate a combination of clinical, laboratory, endoscopic, and radiological parameters to evaluate the disease course of patients with IBD. Unfortunately, the conventional symptom-based therapeutic approach does not improve long-term outcomes and there is no single ideal biomarker available. Endoscopy plays a key role in evaluating response to therapy as well as monitoring disease activity. Recently, bedside intestinal ultrasound (IUS) has gained increasing interest and diffusion as it appears to offer several advantages including the monitoring of therapeutic response.
conclusionIn light of growing clinical advances, we present a schematic evidence-based monitoring algorithm that can be easily applied in clinical practice which combines all major monitoring modalities, including noninvasive tools such as IUS and video-capsule endoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.